Amgen (AMGN) : Appleton Partners Incma scooped up 2,181 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 20,572 shares of Amgen which is valued at $3,357,145.Amgen makes up approximately 0.65% of Appleton Partners Incma’s portfolio.
Amgen closed down -1.85 points or -1.14% at $161 with 27,29,473 shares getting traded on Wednesday. Post opening the session at $162.72, the shares hit an intraday low of $160.5 and an intraday high of $162.9 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Dumont Blake Investment Advisors reduced its stake in AMGN by selling 60 shares or 0.54% in the most recent quarter. The Hedge Fund company now holds 10,960 shares of AMGN which is valued at $1,788,562. Amgen makes up approx 0.92% of Dumont Blake Investment Advisors’s portfolio.Cornerstone Advisors boosted its stake in AMGN in the latest quarter, The investment management firm added 117 additional shares and now holds a total of 423 shares of Amgen which is valued at $69,029. Amgen makes up approx 0.07% of Cornerstone Advisors’s portfolio. Jaffetilchin Investment Partners added AMGN to its portfolio by purchasing 2,704 company shares during the most recent quarter which is valued at $432,992. Amgen makes up approx 0.14% of Jaffetilchin Investment Partners’s portfolio.Abner Herrman Brock boosted its stake in AMGN in the latest quarter, The investment management firm added 25,271 additional shares and now holds a total of 31,136 shares of Amgen which is valued at $4,869,359. Amgen makes up approx 1.23% of Abner Herrman Brock’s portfolio.
On the company’s financial health, Amgen reported $2.61 EPS for the quarter, beating the analyst consensus estimate by $ 0.32 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $2.29. The company had revenue of $5536.00 million for the quarter, compared to analysts expectations of $5534.94 million. The company’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.16 EPS.
Investors should note that on Mar 2, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced May 13, 2016 as the ex-dividend date and fixed the record date on May 17, 2016. The payable date has been fixed on Jun 8, 2016.
Many Wall Street Analysts have commented on Amgen. Citigroup Initiated Amgen on Feb 25, 2016 to “Neutral”, Price Target of the shares are set at $165.Shares were Reiterated by Argus on Feb 8, 2016 to “Buy” and Lowered the Price Target to $ 185 from a previous price target of $202 .
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.